Estonia

Medical Only (Private)

Reimbursed Care Access

Estonia maintains a restrictive controlled‑substances regime: classic psychedelics (psilocybin, MDMA, DMT, mescaline, 2C‑X, 5‑MeO‑DMT, ibogaine, ayahuasca preparations) are scheduled and have no routine medical reimbursement outside authorised clinical research. One exception in clinical psychiatric care is esketamine (Spravato) which holds an EU marketing authorisation and is registered for use — however, its use in Estonia is delivered through medical prescription/clinic pathways and is not generally available as a routinely reimbursed, publicly funded antidepressant therapy. Ketamine itself remains a licensed anaesthetic and is used off‑label in some private psychiatric settings for treatment‑resistant depression, typically without public reimbursement for the psychiatric indication.

Read Full Access Guide View Active Trials

Clinical Trials in Estonia

RecruitingPhase NA

Effect of Psychedelic VR-augmented Therapy on Patients With Clinical Depression

This randomised controlled trial (n=45) evaluates a 55-minute psychedelic-like VR intervention (Psyrreal) versus a non-psychedelic VR analogue and a conditional waitlist in adults with clinical depression.

Started: November 6, 2023
Type: interventional
Blinding: double
Randomized: Yes
Registry ID: NCT06174285

CompletedPhase III

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE I)

Double-blind, randomised, placebo-controlled Phase III trial (n=226) testing intranasal esketamine 84 mg twice weekly for 4 weeks plus standard of care versus intranasal placebo plus standard of care for rapid reduction of MDD symptoms including suicidal ideation in adults at imminent suicide risk.

Started: June 9, 2017
Type: interventional
Blinding: double
Randomized: Yes
Registry ID: NCT03039192

CompletedPhase III

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Open-label, long-term extension Phase III safety study (n≈1148) of esketamine nasal spray (flexible 28–84 mg dosing) in participants with treatment-resistant depression, induction twice weekly for 4 weeks then individualised maintenance.

Started: June 9, 2016
Type: interventional
Blinding: none
Randomized: No
Registry ID: NCT02782104

CompletedPhase III

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1)

Randomized, double-blind, active-controlled Phase III study (n=346) comparing fixed-dose intranasal esketamine (56 mg or 84 mg) plus a newly initiated oral antidepressant versus intranasal placebo plus a newly initiated oral antidepressant in adults with treatment-resistant depression.

Started: August 10, 2015
Type: interventional
Blinding: double
Randomized: Yes
Registry ID: NCT02417064

Estonia

Reimbursed Care Access

Clinical Trials in Estonia

Effect of Psychedelic VR-augmented Therapy on Patients With Clinical Depression

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE I)

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1)

Research Events

Company

Product

Legal